Treatment of Ventilator-associated Pneumonia with High-dose Colistin Under Continuous Veno-venous Hemofiltration

Overview

Journal J Transl Int Med

Publisher Sciendo

Specialty General Medicine

Date 2019 Oct 23

PMID 31637180

Citations 5

Authors

Herbert Spapen

Johan Van Laethem

Maya Hites

An Verdoodt

Marc Diltoer

Patrick M Honore

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: High-dose colistin (COL) ensures adequate treatment of pneumonia caused by multidrug resistant gram-negative bacteria (MDR-GNB) but must be weighed against a higher risk of nephrotoxicity. Continuous veno-venous hemofiltration (CVVH) clears COL by filtering and membrane adsorption that permits to avoid dose accumulation and excessively high peak concentrations. We evaluated clinical/microbiological efficacy of the high-dose COL treatment under CVVH in patients with newly diagnosed MDR-GNB ventilator-associated pneumonia (VAP).

Methods: Observational cohort study in critically ill adult patients with MDR-GNB VAP. Colistimethate sodium (CMS) was administered as a 9 million international units (MIU) of loading dose followed by 3 × 4.5 MIU daily. CVVH was performed over a highly adsorptive membrane. Clinical and microbiological efficacies were assessed at the end of therapy. In survivors, serum creatinine level was evaluated before and at the end of therapy.

Results: Fourteen patients (8 male patients, aged 57 ± 14 years) were consecutively included. Isolated pathogens were in 7, in 5, and other in 2 patients. A favorable clinical response was observed in 9 patients (64%). Full and presumed microbiological eradication was observed in 12 patients (86%). Two patients were diagnosed with Stage 1 acute kidney injury.

Conclusions: In patients with MDR-GNB VAP, CVVH may represent an interesting option to enable effective high-dose COL treatment.

Citing Articles

Pharmacokinetics of polymyxin B in different populations: a systematic review.

Wang X, Xiong W, Zhong M, Liu Y, Xiong Y, Yi X Eur J Clin Pharmacol. 2024; 80(6):813-826.

PMID: 38483544 DOI: 10.1007/s00228-024-03666-w.

Plasma concentrations of Colistin sulfate in a patient with septic shock on extracorporeal membrane oxygenation and continuous renal replacement therapy: a case report.

Peng D, Zhang F, Lv P, Chen Y, Yang J, Zhu W Ann Transl Med. 2022; 10(10):614.

PMID: 35722356 PMC: 9201130. DOI: 10.21037/atm-22-2081.

Ventilator-associated pneumonia prevention in the Intensive care unit using Postpyloric tube feeding in China (VIP study): study protocol for a randomized controlled trial.

Hu L, Peng K, Huang X, Wang Z, Wu Q, Xiao Y Trials. 2022; 23(1):478.

PMID: 35681155 PMC: 9178536. DOI: 10.1186/s13063-022-06407-5.

A nomogram incorporating functional and tubular damage biomarkers to predict the risk of acute kidney injury for septic patients.

Ma J, Deng Y, Lao H, Ouyang X, Liang S, Wang Y BMC Nephrol. 2021; 22(1):176.

PMID: 33985459 PMC: 8120900. DOI: 10.1186/s12882-021-02388-w.

Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy.

Li L, Li X, Xia Y, Chu Y, Zhong H, Li J Front Pharmacol. 2020; 11:786.

PMID: 32547394 PMC: 7273837. DOI: 10.3389/fphar.2020.00786.

References

Bonnassieux M, Duclos A, Schneider A, Schmidt A, Benard S, Cancalon C . Renal Replacement Therapy Modality in the ICU and Renal Recovery at Hospital Discharge. Crit Care Med. 2017; 46(2):e102-e110. DOI: 10.1097/CCM.0000000000002796. View

Nation R, Garonzik S, Thamlikitkul V, Giamarellos-Bourboulis E, Forrest A, Paterson D . Dosing guidance for intravenous colistin in critically-ill patients. Clin Infect Dis. 2016; 64(5):565-571. PMC: 5850520. DOI: 10.1093/cid/ciw839. View

Kalil A, Metersky M, Klompas M, Muscedere J, Sweeney D, Palmer L . Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016; 63(5):e61-e111. PMC: 4981759. DOI: 10.1093/cid/ciw353. View

Garonzik S, Li J, Thamlikitkul V, Paterson D, Shoham S, Jacob J . Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011; 55(7):3284-94. PMC: 3122440. DOI: 10.1128/AAC.01733-10. View

Forrest A, Garonzik S, Thamlikitkul V, Giamarellos-Bourboulis E, Paterson D, Li J . Pharmacokinetic/Toxicodynamic Analysis of Colistin-Associated Acute Kidney Injury in Critically Ill Patients. Antimicrob Agents Chemother. 2017; 61(11). PMC: 5655114. DOI: 10.1128/AAC.01367-17. View

Melsen W, Rovers M, Groenwold R, Bergmans D, Camus C, Bauer T . Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis. 2013; 13(8):665-71. DOI: 10.1016/S1473-3099(13)70081-1. View

Imberti R, Cusato M, Villani P, Carnevale L, Iotti G, Langer M . Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest. 2010; 138(6):1333-9. DOI: 10.1378/chest.10-0463. View

Florescu D, Qiu F, McCartan M, Mindru C, Fey P, Kalil A . What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis. 2012; 54(5):670-80. DOI: 10.1093/cid/cir934. View

Plachouras D, Karvanen M, Friberg L, Papadomichelakis E, Antoniadou A, Tsangaris I . Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother. 2009; 53(8):3430-6. PMC: 2715599. DOI: 10.1128/AAC.01361-08. View

10.

Karaiskos I, Friberg L, Galani L, Ioannidis K, Katsouda E, Athanassa Z . Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration. Int J Antimicrob Agents. 2016; 48(3):337-41. DOI: 10.1016/j.ijantimicag.2016.06.008. View

11.

Trifi A, Abdellatif S, Daly F, Mahjoub K, Nasri R, Oueslati M . Efficacy and Toxicity of High-Dose Colistin in Multidrug-Resistant Gram-Negative Bacilli Infections: A Comparative Study of a Matched Series. Chemotherapy. 2016; 61(4):190-6. DOI: 10.1159/000442786. View

12.

Li J, Nation R, Turnidge J, Milne R, Coulthard K, Rayner C . Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006; 6(9):589-601. DOI: 10.1016/S1473-3099(06)70580-1. View

13.

Pogue J, Lee J, Marchaim D, Yee V, Zhao J, Chopra T . Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011; 53(9):879-84. DOI: 10.1093/cid/cir611. View

14.

Omrani A, Alfahad W, Shoukri M, Baadani A, Aldalbahi S, Almitwazi A . High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia. Ann Clin Microbiol Antimicrob. 2015; 14:3. PMC: 4301664. DOI: 10.1186/s12941-015-0062-8. View

15.

Paul M, Daikos G, Durante-Mangoni E, Yahav D, Carmeli Y, Dishon Benattar Y . Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018; 18(4):391-400. DOI: 10.1016/S1473-3099(18)30099-9. View

16.

Silversides J, Fitzgerald E, Manickavasagam U, Lapinsky S, Nisenbaum R, Hemmings N . Deresuscitation of Patients With Iatrogenic Fluid Overload Is Associated With Reduced Mortality in Critical Illness. Crit Care Med. 2018; 46(10):1600-1607. DOI: 10.1097/CCM.0000000000003276. View

17.

Honore P, Jacobs R, Joannes-Boyau O, De Regt J, De Waele E, Van Gorp V . Newly designed CRRT membranes for sepsis and SIRS--a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic structured review. ASAIO J. 2013; 59(2):99-106. DOI: 10.1097/MAT.0b013e3182816a75. View

18.

Tuon F, Rigatto M, Lopes C, Kamei L, Rocha J, Zavascki A . Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents. 2014; 43(4):349-52. DOI: 10.1016/j.ijantimicag.2013.12.002. View

19.

Honore P, Jacobs R, De Waele E, Spapen H . Applying pharmacokinetic/pharmacodynamic principles for optimizing antimicrobial therapy during continuous renal replacement therapy. Anaesthesiol Intensive Ther. 2017; 49(5):412-418. DOI: 10.5603/AIT.a2017.0071. View

20.

Cheah S, Wang J, Nguyen V, Turnidge J, Li J, Nation R . New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection. J Antimicrob Chemother. 2015; 70(12):3291-7. DOI: 10.1093/jac/dkv267. View